Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00871910 | Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | completed | Phase 1 | 81 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 23, 2017 | clinicaltrials |
| NCT01473095 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | completed | Phase 1 | 120 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY |
| 1 |
| Oct 23, 2017 |
| clinicaltrials |
| NCT01159522 | A Dose Escalation Study of SCB01A in Subjects With Advanced Solid Tumors Who Have Failed Standard Therapy | completed | Phase 1 | 33 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01749384 | Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2017 | clinicaltrials |
| NCT00499135 | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2017 | clinicaltrials |
| NCT01252095 | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours | terminated | Phase 1 | 4 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT02042781 | Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | completed | Phase 1 | 23 | Zucero Pty LtdINDUSTRY | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01581541 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment | terminated | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2017 | clinicaltrials |
| NCT02100007 | ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | MEI Pharma, Inc.INDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT00136578 | Ispinesib In Combination With Carboplatin In Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Sep 25, 2017 | clinicaltrials |
| NCT00572078 | Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors | completed | Phase 1 | 27 | Safi ShahdaOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01485042 | Dose Escalation Study of Pazopanib Plus TH-302(PATH) | completed | Phase 1 | 50 | Herbert Hurwitz, MDOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01851265 | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT01263145 | MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2017 | clinicaltrials |
| NCT03260179 | Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 | unknown | Phase 1 | 60 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | terminated | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01955473 | Japanese Phase 1 Trial of Sym004 in Solid Tumors | completed | Phase 1 | 51 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01302405 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 23 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00541359 | Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 54 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01610479 | A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT00728468 | A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients | completed | Phase 1 | 16 | PfizerINDUSTRY | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00471562 | Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00776867 | Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors | completed | Phase 1 | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00742131 | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors | completed | Phase 1 | 40 | GlaxoSmithKlineINDUSTRY | 0 | Jul 31, 2017 | clinicaltrials |
| NCT02674555 | A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jul 28, 2017 | clinicaltrials |
| NCT00743067 | A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors | completed | Phase 1 | 37 | GlaxoSmithKlineINDUSTRY | 0 | Jul 26, 2017 | clinicaltrials |
| NCT00695448 | Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma | terminated | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Jul 25, 2017 | clinicaltrials |
| NCT02870036 | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 243 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00968981 | A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT00742261 | A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00322140 | CDDO to Treat Solid Tumors and Lymphomas | completed | Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00553189 | Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01453283 | Tabectedin to Treat Children and Adolescents With Cancer | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02428036 | A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions | completed | Phase 1 | 6 | Takara Bio Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02205333 | A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies(MEDI6469) | terminated | Phase 1 / Phase 2 | 48 | MedImmune LLCINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT02412462 | Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | completed | Phase 1 | 15 | Alethia BiotherapeuticsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00861328 | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | completed | Phase 1 | 18 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT00861783 | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma | completed | Phase 1 | 16 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01125891 | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors | completed | Phase 1 | 39 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01165905 | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors | completed | Phase 1 | 10 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01168011 | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors | completed | Phase 1 | 68 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01538537 | Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer | completed | Phase 1 | 29 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT01538563 | Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | completed | Phase 1 | 42 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 23, 2017 | clinicaltrials |
| NCT00977067 | A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | terminated | Phase 1 | 40 | Genentech, Inc.INDUSTRY | 0 | Jun 21, 2017 | clinicaltrials |
| NCT01670175 | Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT02052492 | Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 24 | Efranat Ltd.INDUSTRY | 1 | Jun 20, 2017 | clinicaltrials |
| NCT03182803 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03182816 | CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Oct 23, 2017source: clinicaltrials